Anzeige
Erschienen in:
18.10.2016 | Original Article
Levels of metabolic markers in drug-naive prediabetic and type 2 diabetic patients
Erschienen in: Acta Diabetologica | Ausgabe 2/2017
Einloggen, um Zugang zu erhaltenAbstract
Aims
Type 2 diabetes mellitus (T2DM) and prediabetes (pre-DM) are associated with changes in levels of metabolic markers. The main aim of this study is to compare the levels of omentin, irisin, endothelin-1, nesfatin, hepatocyte growth factor (HGF), fibroblast growth factor, and oxytocin (OXT) between normoglycemic and pre-DM/T2DM obese Jordanian patients.
Methods
One hundred and ninety-eight adult Jordanian subjects were recruited. Demographic data and clinical parameters were collected.
The serum levels of biomarkers were measured by enzymatic assay procedure.
Results
Compared to normoglycemic (95 subjects), pre-DM/T2DM (103 subjects) displayed higher HGF (ng/ml) = 78.8 (71.4–104) versus 55.9 (45.3–66.6), p < 0.0001; and nesfatin (ng/ml) = 0.5 (0.4–0.7) versus 0.2 (0.1–0.4), p < 0.0001; betatrophin (ng/ml) = 1.2 (0.8–1.6) versus 0.22 (0.15–0.41), p < 0.0001. On the other hand, they had lower levels of omentin (ng/ml) = 2.1 (0.9–3.3) versus 3.6 (2.0–6.4), p < 0.0001, irisin (ng/ml) = 113.7 (88.9–142.9) versus 132.6 (110.7–147.8), p < 0.0001; and oxytocin (pg/ml) = 1077.9 (667.3–1506.0) versus 2180.1 (1464.5–2795.6), p < 0.0001; respectively. In comparison, FGF-21 (ng/ml) = 0.3 (0.2–0.5) versus 0.2 (0.1–0.4), and endothelin (pg/ml) = 2.7 (1.3–5.2) versus 2.8 (1.6–5.6) did not differ between the two groups (p > 0.05).
Conclusions
In the present study, patients with pre-DM and T2DM have higher serum levels of metabolic HGF, nesfatin, and betatrophin and lower levels of omentin, irisin, and OXT. Future longitudinal and interventional studies are required to confirm the utility of these markers as novel progression or therapeutic targets in the pharmacotherapy of diabetes.